title: BCR-ABL1-positive and JAK2 V617F-positive clones in 23 patients with both aberrations reveal biologic and clinical importance.
authors: Munich Leukaemia Laboratory GmbH, Munich, Germany.
authors: Pedro
authors: P
authors: Martin-Cabrera
authors: Munich Leukaemia Laboratory GmbH, Munich, Germany.
authors: Claudia
authors: C
authors: Haferlach
authors: Munich Leukaemia Laboratory GmbH, Munich, Germany.
authors: Wolfgang
authors: W
authors: Kern
authors: Munich Leukaemia Laboratory GmbH, Munich, Germany.
authors: Susanne
authors: S
authors: Schnittger
authors: Munich Leukaemia Laboratory GmbH, Munich, Germany.
authors: Torsten
authors: T
authors: Haferlach
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002999:Clone Cells; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009196:Myeloproliferative Disorders / Q000201:enzymology* / Q000235:genetics*
chemical_list: C581634:BCR-ABL1 fusion protein, human; D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2
keywords: 
  BCR-ABL1
  ; JAK2 V617F; chronic myeloid leukaemia; myeloproliferative neoplasm